# Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)

> **NCT02818998** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 463 (actual)

## Conditions studied

- Macular Edema

## Interventions

- **DRUG:** Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT02818998
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-16
- **Primary completion:** 2018-11-13
- **Final completion:** 2019-09-24
- **Target enrollment:** 463 (ACTUAL)
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02818998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02818998, "Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02818998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*